Skip to main content
MyPeptideMatch logoMyPeptideMatch
Reviewed by MyPeptideMatch Editorial TeamLast reviewed February 2026Updated February 2026

FOXO4-DRI Dosing Protocol: 10 mg Vial — Senolytic Clearance Guide

FOXO4-DRI retro-inverso peptide senolytic protocol — targeted clearance of senescent cells for longevity, recovery, and tissue rejuvenation.

Go to peptide profileCalculate your dose

Quickstart highlights

FOXO4-DRI is a D-amino acid retro-inverso peptide designed to interfere with the FOXO4-p53 interaction that allows senescent cells to evade apoptosis.

  • Concentration: 2 mg/mL (10 mg vial + 5 mL bacteriostatic water).
  • At 2 mg/mL: 2.5 mg = 125 units, 5 mg = 250 units per injection.
  • Baar et al. 2017: FOXO4-DRI selectively induces apoptosis in senescent cells while sparing normal cells in murine models.
  • Protocol: 3 consecutive injection days per week; rest 4 days to allow senescent cell clearance.
  • Store lyophilized at -20 °C; reconstituted solution at 2–8 °C, use within 14 days.

Dosing table

For educational reference only. Your prescribing provider may adjust doses based on your clinical profile and response.

WeekDose (µg)UnitsFrequencyNotes
1100050Once daily x 3 consecutive days (Mon-Wed)1 mg — 50 units; test dose; assess injection site reactions and systemic response
2-42500125Once daily x 3 consecutive days per week2.5 mg — 125 units; intermediate dose; one 10 mg vial covers ~4 three-day sessions
5-85000250Once daily x 3 consecutive days per week5 mg — 250 units (full strength); Baar et al. 2017 mouse equivalent dose; 10 mg vial = 2 three-day sessions

Reconstitution steps

  1. Draw 5 mL bacteriostatic water (two 2.5 mL draws); inject slowly down the vial wall.
  2. Swirl gently until dissolved; do not shake.
  3. Final concentration: 2 mg/mL. At 2 mg/mL: 2.5 mg = 125 units, 5 mg = 250 units.
  4. Label with date; refrigerate at 2–8 °C. Use within 28 days.

Supplies needed

8_week-week plan

  • 4 vials
  • 24 syringes
  • 20 mL bac water
  • 24 alcohol swabs
Need clinics? See vetted providers →

Protocol overview & cycle notes

Selectively eliminate p53/FOXO4-complex-dependent senescent cells through FOXO4-DRI-mediated apoptosis induction, reducing senescent cell burden and associated pro-inflammatory SASP secretome.

Cycle length: 8 weeks on.

Off-cycle: 12–16 weeks off after 8-week senolytic course; assess biomarkers before repeating.

Storage & handling

Lyophilized: store at -20 °C for maximum stability. Reconstituted at 2 mg/mL: refrigerate 2–8 °C; use within 14 days. FOXO4-DRI is a D-retro-inverso peptide — more stable to proteolysis than standard L-amino acid peptides but still benefits from cold storage.

Injection & tracking tips

  • Inject subcutaneously on 3 consecutive days per week (e.g., Monday-Wednesday); rest the remaining 4 days to allow senescent cell apoptosis to complete.
  • Rotate injection sites — abdomen, outer thigh, upper arm — to minimize local tissue response from senescent cell clearance.
  • Some users experience transient injection site inflammation and mild fatigue during the 3-day active period — this may reflect local senescent cell clearance.

Tracking

Logging helps you and your provider spot patterns and adjust dose or timing.

  • Test p16/p21 senescent cell biomarkers (if accessible through specialty labs) at baseline and 12 weeks post-course.
  • Track inflammatory markers: hsCRP, IL-6, TNF-alpha at baseline and 8 weeks.
  • Record physical performance metrics: grip strength, 6MWT, reaction time monthly.
Log your cycle in the calculator →

How this works & references

FOXO4-DRI is a D-amino acid retro-inverso peptide designed to interfere with the FOXO4-p53 interaction that allows senescent cells to evade apoptosis. Senescent cells accumulate with aging, expressing an anti-apoptotic shield mediated by nuclear FOXO4 sequestering p53 away from mitochondria. FOXO4-DRI competes with endogenous FOXO4, freeing p53 to initiate mitochondrial apoptosis specifically in senescent cells (which depend on this survival mechanism) while sparing normal cells with intact pro-survival signaling. Baar et al. (2017, Nature Medicine) demonstrated: (1) Selective senescent cell apoptosis in murine aging models; (2) Improved exercise capacity and fur density in old mice; (3) Enhanced survival in fast-aging XFE progeroid mice after FOXO4-DRI treatment. No published human clinical trials as of 2026.

Sources

Frequently asked questions

Is FOXO4-DRI safe for humans based on current evidence?
No completed human clinical trials exist as of 2026. All published efficacy data is from murine models (Baar et al., 2017). The mechanism is theoretically selective for senescent cells, but off-target apoptosis in non-senescent cells with FOXO4-p53 activity cannot be excluded in humans. This is a high-risk, low-evidence intervention. Use only under physician supervision with informed consent about experimental nature.
What makes FOXO4-DRI different from other senolytics like quercetin or dasatinib?
Quercetin and dasatinib (the most-studied pharmacological senolytics) inhibit anti-apoptotic BCL-2 family proteins broadly — effective but less specific. FOXO4-DRI targets the FOXO4-p53 nuclear interaction specifically, which is characteristic of senescent cells' survival mechanism, potentially offering more precise selectivity. However, quercetin and dasatinib have published human evidence (Mayo Clinic IPF trial); FOXO4-DRI does not.
How long after a FOXO4-DRI course does senescent cell burden decrease?
Mouse data shows measurable reduction in p16Ink4a-positive (senescent marker) cells within 3 weeks of FOXO4-DRI treatment. Human clearance timeline is unknown. Inflammatory biomarkers (IL-6, TNF-alpha) from the senescent cell SASP are expected to decrease within 4–8 weeks of effective senescent cell clearance.
What is the D-retro-inverso (DRI) modification and why does it matter?
Standard L-amino acid peptides are rapidly degraded by blood and tissue proteases. FOXO4-DRI is synthesized with D-amino acids (mirror-image chirality) in reverse sequence — this creates a peptide that folds identically to the L-version at the binding site but is resistant to protease degradation. This dramatically increases the half-life in vivo from minutes (L-peptide) to hours (D-retro-inverso), enabling subcutaneous injection with adequate systemic exposure.
How many 10 mg vials do I need for an 8-week protocol at 5 mg per injection?
At 5 mg per injection, 3 injections per week = 15 mg per week. Over 8 weeks = 120 mg total. At 10 mg per vial: 12 vials needed for a full 8-week course at 5 mg 3x/week. Many practitioners start at lower doses (1–2.5 mg) to reduce cost and assess tolerability, significantly reducing vial count.

Related protocols

Vilon Dosing Protocol: 20 mg Vial — Dipeptide Immune & Longevity Bioregulator Guide

Vilon (Lys-Glu dipeptide) Russian immune and longevity bioregulator dosing guide — the simplest Khavinson bioregulator for systemic immune normalization and longevity support.

View protocol

Vesugen Dosing Protocol: 20 mg Vial — Vascular Bioregulator & Cardiovascular Guide

Vesugen (Lys-Glu-Asp tetrapeptide) Russian vascular bioregulator dosing guide — endothelial cell gene normalization for arterial health, blood pressure regulation, and cardiovascular aging.

View protocol

Testagen Dosing Protocol: 20 mg Vial — Testicular Bioregulator & Testosterone Support Guide

Testagen (Lys-Glu-Asp-Gly tetrapeptide) Russian testicular bioregulator dosing guide — Leydig cell gene normalization for testosterone production optimization and male reproductive aging support.

View protocol

Prostamax Dosing Protocol: 20 mg Vial — Prostate Bioregulator Guide

Prostamax (Lys-Asp-Glu-Leu tetrapeptide) Russian prostate bioregulator dosing guide — prostatic epithelial gene normalization for BPH, prostate aging, and urinary symptom support.

View protocol

This content is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting any peptide therapy. Dosing and protocols may vary by formulation and prescriber.

Need help?

Browse vetted clinicsView full peptide profile →